Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medx Health Corp V.MDX

Alternate Symbol(s):  MDXHF

MedX Health Corp. is a medical device and software company. It develops and manufactures skin-related screening tools and phototherapy devices for pain relief and tissue repair. It focuses on skin health with its SIAscopy on DermSecure telemedicine platform, utilizing its SIAscopy technology. SIAscopy is a medical device technology that is used to scan skin for suspicious moles and lesions and, including DermSecure, its telemedicine software application, and phototherapeutic medical devices, which use light energy in lower-level laser and light-emitting diode to provide treatment of pain and tissue damage in the rehabilitation market. Its products SIAMETRICS, SIMSYS, and MoleMate include hand-held devices that use patented technology utilizing light and its remittance to view up to two millimeters beneath suspicious moles and lesions in a pain free, non-invasive manner. Its SIAscopy on DermSecure telemedicine platform enables the Web-based operation of its SIAscopy scanning technology.


TSXV:MDX - Post by User

Bullboard Posts
Post by Insightful1on Jun 19, 2020 8:55am
156 Views
Post# 31168457

Scoot's departure

Scoot's departureScott Spearn was never been touted as the be all and end all. Scott has a family issue which he felt was in need of all of his attention.

MedX has given guidance to expect revenue from the new platform starting in Q2 and building in Q3-4 how you determined there is no revenue when MedX hasn't reported is beyond my comprehension. MedX just partnered in Mexico which if you read the announcement carefully you woul discover has a huge issue with melanoma because of awareness and the late stage  when melanomas are discovered. 120 million population market. I would suggest to watch the Agoracom video as it gives great clarity in where MedX is positioned currently.

MedX just completed a successful financing and has hired additional sales execs to the team. The writing on the wall is, MedX is in the best place it has ever been. Robert vonder Porten stepping into the role of CEO will be seamless as he was the previous President and CEO so in the immortal words of Shakespeare "Much Ado about Nothing".

Bullboard Posts